Literature DB >> 10588007

Classical swine fever: the European experience and a guide for infected areas.

J Vandeputte1, G Chappuis.   

Abstract

Classical swine fever (CSF) (hog cholera) virus infection is still of world-wide concern, either because of the direct effects of the disease on swine breeding in areas where the virus is epizootic or enzootic, or as a threat in areas where the virus has been eradicated. The authors provide an overview of the characteristics of the disease. Special emphasis is placed on the chronic form of disease, particularly in the late stages of eradication programmes. In the early 1980s, the European Union (EU) was composed of countries which were officially free of the disease (absence of infection and no vaccination) and countries in which vaccination was either permitted or was compulsory. To ensure free trade between the Member States, an eradication plan was agreed upon and implemented. Initially, the plan consisted of a combination of vaccination with the Chinese strain of the virus and slaughter and removal of infected herds. Consequently, when the number of infected herds was low, vaccination was abandoned and the control of CSF was conducted exclusively by eradication (removal and slaughter). The United Kingdom, Austria, Denmark, Ireland, Luxembourg, Finland and Sweden ceased vaccination before 1980. In the other countries, vaccination was useful in controlling the last epidemics and was finally ceased as follows: France in 1983, the Netherlands in 1986, Belgium, Spain and Greece in 1988, Germany in 1989 and Italy in 1990. From 1990 onwards, no vaccination against CSF has been performed in the EU. New techniques for the diagnosis of CSF (for example, the enzyme-linked immunosorbent assay based on the detection of the p125 antigen of the virus) have been shown to be of value in the early detection of infected animals. In enzootic areas, the use of vaccines based on the Chinese strain has been successful. Vaccines with at least 100 PD50 of virus per dose are able to significantly limit the replication of virulent virus in the tonsils. Consequently, shedding of virus after infection can be reduced considerably. In heavily infected areas, vaccination plays a crucial role. The European experience shows that eradication may be achieved when vaccination with highly effective vaccines is combined with effective identification of swine, movement control, early diagnosis and the rapid elimination of infected herds.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588007     DOI: 10.20506/rst.18.3.1192

Source DB:  PubMed          Journal:  Rev Sci Tech        ISSN: 0253-1933            Impact factor:   1.181


  5 in total

1.  Molecular typing and phylogenetic analysis of classical swine fever virus isolates from Kerala, India.

Authors:  Nimisha Bhaskar; Chintu Ravishankar; R Rajasekhar; K Sumod; T G Sumithra; Koshy John; M Mini; Reghu Ravindran; Shiju Shaji; J Aishwarya
Journal:  Virusdisease       Date:  2015-08-30

2.  Crystal Structure of Classical Swine Fever Virus NS5B Reveals a Novel N-Terminal Domain.

Authors:  Weiwei Li; Baixing Wu; Wibowo Adian Soca; Lei An
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

3.  Clustering of classical swine fever virus isolates by codon pair bias.

Authors:  Immanuel Leifer; Dirk Hoeper; Sandra Blome; Martin Beer; Nicolas Ruggli
Journal:  BMC Res Notes       Date:  2011-11-29

4.  Challenge of pigs with classical swine fever viruses after C-strain vaccination reveals remarkably rapid protection and insights into early immunity.

Authors:  Simon P Graham; Helen E Everett; Felicity J Haines; Helen L Johns; Olubukola A Sosan; Francisco J Salguero; Derek J Clifford; Falko Steinbach; Trevor W Drew; Helen R Crooke
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

5.  Transfection of RNA from organ samples of infected animals represents a highly sensitive method for virus detection and recovery of classical swine fever virus.

Authors:  Denise Meyer; Stefanie Schmeiser; Alexander Postel; Paul Becher
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.